{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019869","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.254681+00:00","generated_at":"2026-06-25T17:30:27.664085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Iridex Q1 revenue $13.4M (record), up 12% YoY; net loss $2.4M; guides FY22 rev $57-59M","bullets":["Record Q1 revenue $13.4M (+12% YoY); net loss $2.4M ($0.15/sh) vs $2.0M ($0.14/sh) prior year.","Cyclo G6 product revenue $3.5M (+6%); 14,700 probes sold (+8%). Retina revenue $7.3M (+10%).","Gross margin improved to 44.6% from 41.3%. Cash $20.6M; net cash used $3.2M in Q1.","FY2022 guidance: revenue $57-59M; Cyclo G6 probe sales 67k-70k (15-20% growth).","CEO cites continued adoption of MicroPulse TLT and steps to mitigate supply chain risks."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019869","json":"https://secwatch.observer/filing/0001564590-22-019869.json","markdown":"https://secwatch.observer/filing/0001564590-22-019869.md","text":"https://secwatch.observer/filing/0001564590-22-019869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000156459022019869/0001564590-22-019869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000156459022019869/irix-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:30:27.664085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}